

# David V Sheehan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4846255/david-v-sheehan-publications-by-year.pdf>

**Version:** 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

137  
papers

10,853  
citations

43  
h-index

103  
g-index

148  
ext. papers

12,130  
ext. citations

4.6  
avg, IF

5.64  
L-index

#	Paper	IF	Citations
137	Evaluating functional disability in clinical trials of lisdexamfetamine dimesylate in binge eating disorder using the Sheehan Disability Scale. <i>International Journal of Methods in Psychiatric Research</i> , <b>2021</b> , 30, e1849	4.3	1
136	Pilot Mental Health Survey, Nepal: Lessons Learned for Survey Design and Instrumentation. <i>Innovations in Clinical Neuroscience</i> , <b>2020</b> , 17, 17-23	1	
135	THE DEPRESSION INVENTORY DEVELOPMENT SCALE: Assessment of Psychometric Properties Using Classical and Modern Measurement Theory in a CAN-BIND Trial. <i>Innovations in Clinical Neuroscience</i> , <b>2020</b> , 17, 30-40	1	3
134	Cross-Validation of the Arabic Mini International Neuropsychiatric Interview, Module K, for Diagnosis of Schizophrenia and the Arabic Positive and Negative Syndrome Scale. <i>Journal of Psychopathology and Behavioral Assessment</i> , <b>2020</b> , 42, 139-149	2	1
133	Effects of Lisdexamfetamine Dimesylate on Functional Impairment Measured on the Sheehan Disability Scale in Adults With Moderate-to-severe Binge Eating Disorder: Results from Two Randomized, Placebo-controlled Trials. <i>Innovations in Clinical Neuroscience</i> , <b>2018</b> , 15, 22-29	1	4
132	Restoring function in major depressive disorder: A systematic review. <i>Journal of Affective Disorders</i> , <b>2017</b> , 215, 299-313	6.6	68
131	The effect of vortioxetine on overall patient functioning in patients with major depressive disorder. <i>Brain and Behavior</i> , <b>2017</b> , 7, e00622	3.4	13
130	Brexipiprazole as an adjunctive treatment in young adults with major depressive disorder who are in a school or work environment. <i>Journal of Affective Disorders</i> , <b>2016</b> , 204, 40-7	6.6	12
129	A systematic review of the health-related quality of life and economic burdens of anorexia nervosa, bulimia nervosa, and binge eating disorder. <i>Eating and Weight Disorders</i> , <b>2016</b> , 21, 353-364	3.6	139
128	The Depression Inventory Development Workgroup: A Collaborative, Empirically Driven Initiative to Develop a New Assessment Tool for Major Depressive Disorder. <i>Innovations in Clinical Neuroscience</i> , <b>2016</b> , 13, 20-31	1	8
127	Importance of Restoring Function in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, e908	4.6	3
126	Assessing the Reliability and Validity of the Sheehan Irritability Scale in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 1080-6	4.6	5
125	Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial. <i>Journal of Clinical Psychiatry</i> , <b>2016</b> , 77, 1687-1694	4.6	15
124	Content validity of the Sheehan Irritability Scale in patients with major depressive disorder. <i>International Clinical Psychopharmacology</i> , <b>2016</b> , 31, 110-7	2.2	2
123	Assessment of functional outcomes by Sheehan Disability Scale in patients with major depressive disorder treated with duloxetine versus selective serotonin reuptake inhibitors. <i>Human Psychopharmacology</i> , <b>2016</b> , 31, 53-63	2.3	12
122	The Psychological and Medical Factors Associated With Untreated Binge Eating Disorder. <i>primary care companion for CNS disorders, The</i> , <b>2015</b> , 17,	1.2	24
121	A phase III, double-blind, placebo-controlled, flexible-dose study of levomilnacipran extended-release in patients with major depressive disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2014</b> , 34, 47-56	1.7	61

120	Linguistic Validation of the Pediatric Versions of the Sheehan Suicidality Tracking Scale (S-STs). <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 141-63	1	5
119	The complexity of assessing overall severity of suicidality: a case study. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 164-71	1	1
118	Do the Five Combinations of Suicidal Ideation in the FDA 2012 Draft Guidance Document and the C-SSRS Adequately Cover All Suicidal Ideation Combinations in Practice? A Case Study. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 172-8	1	4
117	Is a count of suicidal ideation and behavior events useful in assessing global severity of suicidality? A case study. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 179-81	1	1
116	Is There Value in Asking the Question "Do you think you would be better off dead?" in Assessing Suicidality? A Case Study. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 182-90	1	10
115	How the Timing of a Patient's Self-ratings of Suicidality and the Relationship to the Recipient Affect Patient Responses: A Case Study. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 191-3	1	
114	Comparative Validation of the S-STs, the ISST-Plus, and the C-SSRS for Assessing the Suicidal Thinking and Behavior FDA 2012 Suicidality Categories. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 32-46	1	14
113	Simple Measures of Hopelessness and Impulsivity are Associated with Acute Suicidal Ideation and Attempts in Patients in Psychiatric Crisis. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 47-53	1	11
112	Current Assessment and Classification of Suicidal Phenomena using the FDA 2012 Draft Guidance Document on Suicide Assessment: A Critical Review. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 54-65 <sup>1</sup>	1	4
111	The Columbia-Suicide Severity Rating Scale (C-SSRS): Has the "Gold Standard" Become a Liability?. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 66-80	1	46
110	Status Update on the Sheehan-Suicidality Tracking Scale (S-STs) 2014. <i>Innovations in Clinical Neuroscience</i> , <b>2014</b> , 11, 93-140	1	12
109	A randomized, double-blind, placebo-controlled study of ziprasidone monotherapy in bipolar disorder with co-occurring lifetime panic or generalized anxiety disorder. <i>Journal of Clinical Psychiatry</i> , <b>2014</b> , 75, 77-84	4.6	19
108	Characteristics of responders and non-responders to risperidone monotherapy or placebo in co-occurring bipolar disorder and anxiety disorder. <i>European Psychiatry</i> , <b>2013</b> , 28, 190-6	6	4
107	Effects of extended-release quetiapine fumarate on long-term functioning and sleep quality in patients with Generalized Anxiety Disorder (GAD): data from a randomized-withdrawal, placebo-controlled maintenance study. <i>Journal of Affective Disorders</i> , <b>2013</b> , 151, 906-13	6.6	11
106	Randomized, placebo-controlled trial of quetiapine XR and divalproex ER monotherapies in the treatment of the anxious bipolar patient. <i>Journal of Affective Disorders</i> , <b>2013</b> , 145, 83-94	6.6	31
105	Sheehan Suicidality Tracking Scale (S-STs): reliability, convergent and discriminative validity in young Italian adults. <i>Comprehensive Psychiatry</i> , <b>2013</b> , 54, 842-9	7.3	12
104	Relationship between major depressive disorder and associated painful physical symptoms: analysis of data from two pooled placebo-controlled, randomized studies of duloxetine. <i>International Clinical Psychopharmacology</i> , <b>2013</b> , 28, 330-8	2.2	14
103	Humanistic and economic burden of generalized anxiety disorder in North America and Europe. <i>Journal of Affective Disorders</i> , <b>2012</b> , 140, 103-12	6.6	77

102	Vortioxetine (Lu AA21004) 5 mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 858-66	1.2	41
101	Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial. <i>European Neuropsychopharmacology</i> , <b>2012</b> , 22, 847-57	1.2	54
100	Generalized anxiety disorder. <i>Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn</i> , <b>2012</b> , 106, 343-62	3	10
99	Evaluation of the effect of duloxetine treatment on functioning as measured by the Sheehan disability scale: pooled analysis of data from six randomized, double-blind, placebo-controlled clinical studies. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 27, 298-309	2.2	19
98	Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate. <i>International Clinical Psychopharmacology</i> , <b>2012</b> , 27, 239-48	2.2	6
97	Antidepressant use in geriatric populations: the burden of side effects and interactions and their impact on adherence and costs. <i>American Journal of Geriatric Psychiatry</i> , <b>2011</b> , 19, 211-21	6.5	72
96	Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan disability scale. <i>International Clinical Psychopharmacology</i> , <b>2011</b> , 26, 75-83	2.2	75
95	Clinical and functional outcomes in patients with major depressive disorder and painful physical symptoms switched to treatment with duloxetine. <i>Human Psychopharmacology</i> , <b>2011</b> , 26, 242-51	2.3	11
94	Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. <i>Journal of Clinical Psychiatry</i> , <b>2011</b> , 72, 914-28	4.6	58
93	Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees. <i>Annals of Clinical Psychiatry</i> , <b>2011</b> , 23, 285-96 <sup>1.4</sup>	1.4	6
92	Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a consensus statement. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, e1-e21	4.6	81
91	Reliability and validity of the Mini International Neuropsychiatric Interview for Children and Adolescents (MINI-KID). <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 313-26	4.6	76 <sup>1</sup>
90	Suicidality and risk of suicide--definition, drug safety concerns, and a necessary target for drug development: a brief report. <i>Journal of Clinical Psychiatry</i> , <b>2010</b> , 71, 1040-6	4.6	44
89	Adequacy of pharmacotherapy among medicaid-enrolled patients newly diagnosed with obsessive-compulsive disorder. <i>CNS Spectrums</i> , <b>2009</b> , 14, 695-703	1.8	4
88	Randomized, placebo-controlled trial of risperidone for acute treatment of bipolar anxiety. <i>Journal of Affective Disorders</i> , <b>2009</b> , 115, 376-85	6.6	52
87	Atypical antipsychotics in primary generalized anxiety disorder or comorbid with mood disorders. <i>Expert Review of Neurotherapeutics</i> , <b>2009</b> , 9, 1147-58	4.3	31
86	Placebo-controlled inpatient comparison of venlafaxine and fluoxetine for the treatment of major depression with melancholic features. <i>International Clinical Psychopharmacology</i> , <b>2009</b> , 24, 61-86	2.2	12
85	An evidence-based review of the clinical use of sertraline in mood and anxiety disorders. <i>International Clinical Psychopharmacology</i> , <b>2009</b> , 24, 43-60	2.2	27

84	Zolpidem extended-release improves sleep and next-day symptoms in comorbid insomnia and generalized anxiety disorder. <i>Journal of Clinical Psychopharmacology</i> , <b>2009</b> , 29, 222-30	1.7	57
83	Extended-release Trazodone in Major Depressive Disorder: A Randomized, Double-blind, Placebo-controlled Study. <i>Psychiatry</i> , <b>2009</b> , 6, 20-33		10
82	The efficacy and tolerability of once-daily controlled-release trazodone for depressed mood, anxiety, insomnia, and suicidality in major depressive disorder. <i>Psychopharmacology Bulletin</i> , <b>2009</b> , 42, 5-22	0.9	39
81	Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders. <i>CNS Drugs</i> , <b>2008</b> , 22, 963-73	6.7	64
80	Estimates of serotonin and norepinephrine transporter inhibition in depressed patients treated with paroxetine or venlafaxine. <i>Neuropsychopharmacology</i> , <b>2008</b> , 33, 3201-12	8.7	41
79	Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. <i>International Clinical Psychopharmacology</i> , <b>2008</b> , 23, 70-83	2.2	237
78	The relationship between functional outcomes and the treatment of anxious and painful somatic symptoms in patients with generalized anxiety disorder. <i>Current Medical Research and Opinion</i> , <b>2008</b> , 24, 2457-66	2.5	19
77	Perceived stress in anxiety disorders and the general population: a study of the Sheehan stress vulnerability scale. <i>Psychiatry Research</i> , <b>2007</b> , 151, 249-54	9.9	21
76	Current approaches to the pharmacologic treatment of anxiety disorders. <i>Psychopharmacology Bulletin</i> , <b>2007</b> , 40, 98-109	0.9	20
75	The speed of onset of action of alprazolam-XR compared to alprazolam-CT in panic disorder. <i>Psychopharmacology Bulletin</i> , <b>2007</b> , 40, 63-81	0.9	12
74	An open-label study of tiagabine in panic disorder. <i>Psychopharmacology Bulletin</i> , <b>2007</b> , 40, 32-40	0.9	10
73	Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. <i>Neuropsychopharmacology</i> , <b>2005</b> , 30, 445-60	8.7	104
72	Efficacy and Tolerability of Controlled-Release Paroxetine in the Treatment of Panic Disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 34-40	4.6	51
71	Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. <i>Journal of Clinical Psychiatry</i> , <b>2005</b> , 66, 34-40	4.6	41
70	Differences in total medical costs across the SSRIs for the treatment of depression and anxiety. <i>American Journal of Managed Care</i> , <b>2005</b> , 11, S354-61	2.1	12
69	Evaluating the economic consequences of early antidepressant treatment discontinuation: a comparison between controlled-release and immediate-release paroxetine. <i>Journal of Clinical Psychopharmacology</i> , <b>2004</b> , 24, 544-8	1.7	19
68	A 37-year-old Woman With Treatment-resistant Panic Disorder - or Is it Bipolar Anxiety?. <i>Psychiatric Annals</i> , <b>2004</b> , 34, 904-910	0.5	
67	Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. <i>American Journal of Psychiatry</i> , <b>2003</b> , 160, 749-56	11.9	155

66	The Tourette <sup>®</sup> Disorder Scale (TODS): development, reliability, and validity. <i>Assessment</i> , <b>2003</b> , 10, 273-87.	3.7	58
65	Paroxetine treatment of generalized anxiety disorder. <i>Psychopharmacology Bulletin</i> , <b>2003</b> , 37 Suppl 1, 64-75	0.9	5
64	Improved tolerability and increased length of therapy. <i>Managed Care</i> , <b>2003</b> , 12, 23-5	0.3	
63	Characterization of the longitudinal course of improvement in generalized anxiety disorder during long-term treatment with venlafaxine XR. <i>Journal of Psychiatric Research</i> , <b>2002</b> , 36, 209-17	5.2	51
62	Neuronal nicotinic receptor inhibition for treating mood disorders: preliminary controlled evidence with mecamylamine. <i>Depression and Anxiety</i> , <b>2002</b> , 16, 89-92	8.4	66
61	Nicotinic acetylcholine receptors as targets for antidepressants. <i>Molecular Psychiatry</i> , <b>2002</b> , 7, 525-35	15.1	230
60	Effect of Hypericum perforatum (St John <sup>®</sup> wort) in major depressive disorder: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2002</b> , 287, 1807-14	27.4	311
59	Generalized anxiety disorder: comorbidity, comparative biology and treatment. <i>International Journal of Neuropsychopharmacology</i> , <b>2002</b> , 5, 315-25	5.8	77
58	Impact of formulary restrictions on the cost-effectiveness of antidepressant treatment. <i>Managed Care Quarterly</i> , <b>2002</b> , 10, 21-31		
57	Family Impact of Tourette <sup>®</sup> Syndrome. <i>Journal of Child and Family Studies</i> , <b>2001</b> , 10, 477-483	2.3	24
56	Social anxiety disorder. <i>Medical Clinics of North America</i> , <b>2001</b> , 85, 711-33	7	15
55	Multicenter, double-blind, placebo-controlled study of mecamylamine monotherapy for Tourette <sup>®</sup> disorder. <i>Journal of the American Academy of Child and Adolescent Psychiatry</i> , <b>2001</b> , 40, 1103-10	7.2	84
54	Have drug companies hyped social anxiety disorder to increase sales. No: Efforts to relieve human suffering deserve rewards. <i>Western Journal of Medicine</i> , <b>2001</b> , 175, 365		
53	Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. <i>American Journal of Psychiatry</i> , <b>2000</b> , 157, 968-74	11.9	192
52	Physician substance use by medical specialty. <i>Journal of Addictive Diseases</i> , <b>1999</b> , 18, 23-37	1.7	112
51	Diagnostic errors of primary care screens for depression and panic disorder. <i>International Journal of Psychiatry in Medicine</i> , <b>1999</b> , 29, 1-11	1	19
50	A diagnostic aid for detecting (DSM-IV) mental disorders in primary care. <i>General Hospital Psychiatry</i> , <b>1998</b> , 20, 1-11	5.6	18
49	DSM-IV-R Psychotic Disorders: procedural validity of the Mini International Neuropsychiatric Interview (MINI). Concordance and causes for discordance with the CIDI. <i>European Psychiatry</i> , <b>1998</b> , 13, 26-34	6	192

48	Mental disorders and disability among patients in a primary care group practice. <i>American Journal of Psychiatry</i> , <b>1997</b> , 154, 1734-40	11.9	287
47	Assessing psychiatric impairment in primary care with the Sheehan Disability Scale. <i>International Journal of Psychiatry in Medicine</i> , <b>1997</b> , 27, 93-105	1	686
46	False positive results: a challenge for psychiatric screening in primary care. <i>American Journal of Psychiatry</i> , <b>1997</b> , 154, 1462-4	11.9	27
45	The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CID-I. <i>European Psychiatry</i> , <b>1997</b> , 12, 224-231	6	2286
44	The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. <i>European Psychiatry</i> , <b>1997</b> , 12, 232-241	6	1326
43	Suicidal ideation in primary care. <i>Journal of General Internal Medicine</i> , <b>1996</b> , 11, 447-53	4	75
42	Method for assessing the duration of therapeutic action and milligram equivalence of anxiolytics. <i>Anxiety</i> , <b>1996</b> , 2, 40-6		2
41	Single ion gas chromatographic/mass spectroscopic quantitative analysis of environmental CO <sub>2</sub> in agoraphobic environments. <i>Anxiety</i> , <b>1994</b> , 1, 275-7		1
40	The relative efficacy of high-dose buspirone and alprazolam in the treatment of panic disorder: a double-blind placebo-controlled study. <i>Acta Psychiatrica Scandinavica</i> , <b>1993</b> , 88, 1-11	6.5	100
39	Resident physician substance use, by specialty. <i>American Journal of Psychiatry</i> , <b>1992</b> , 149, 1348-54	11.9	85
38	Relations among stressors, strains, and substance use among resident physicians. <i>Substance Use and Misuse</i> , <b>1992</b> , 27, 979-94		16
37	Perspectives: Substance Use Among Senior Medical Students: A Survey of 23 Medical Schools. <i>Journal of Addictions Nursing</i> , <b>1992</b> , 4, 72-79	0.7	0
36	Behavioral consequences of job-related stress among resident physicians: the mediating role of psychological strain. <i>Psychological Reports</i> , <b>1991</b> , 69, 339-49	1.6	19
35	Snorting benzodiazepines. <i>American Journal of Drug and Alcohol Abuse</i> , <b>1991</b> , 17, 457-68	3.7	19
34	Is Buspirone Effective for Panic Disorder?. <i>Journal of Clinical Psychopharmacology</i> , <b>1990</b> , 10, 3-11	1.7	87
33	Adinazolam sustained release formulation in the treatment of panic disorder: a pilot study. <i>Irish Journal of Psychological Medicine</i> , <b>1990</b> , 7, 124-128	3	4
32	A double-blind comparison of fluvoxamine, desipramine and placebo in outpatients with depression. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1990</b> , 14, 929-39	5.5	28
31	Adinazolam sustained release formulation in the treatment of generalized anxiety disorder. <i>Journal of Anxiety Disorders</i> , <b>1990</b> , 4, 239-246	10.9	6

30	Panic and Phobias: Empirical Evidence of Models and Longterm Effects of Behavioral Treatments. <i>American Journal of Psychiatry</i> , <b>1990</b> , 147, 1084-1085	11.9	15
29	An Open Study Examining the Diagnosis of Anxiety and the Use of Buspirone in a Primary Care Environment. <i>Drug Investigation</i> , <b>1989</b> , 1, 3-10		3
28	Medical Evaluation of the Anxious Patient. <i>Psychiatric Annals</i> , <b>1988</b> , 18, 176-181	0.5	1
27	Diagnosis and Treatment of Anxiety Disorders in Children and Adolescents. <i>Psychiatric Annals</i> , <b>1988</b> , 18, 146-157	0.5	0
26	Recent developments in the treatment of panic disorder. <i>Acta Psychiatrica Scandinavica</i> , <b>1987</b> , 335, 75-85	5.5	6
25	Benzodiazepines in panic disorder and agoraphobia. <i>Journal of Affective Disorders</i> , <b>1987</b> , 13, 169-81	6.6	38
24	Diagnosis and treatment of pathological anxiety. <i>Stress and Health</i> , <b>1987</b> , 3, 21-32		
23	A case of bupropion-induced seizure. <i>Journal of Nervous and Mental Disease</i> , <b>1986</b> , 174, 496-8	1.8	6
22	A combination drug treatment for acute common migraine. <i>Headache</i> , <b>1986</b> , 26, 231-6	4.2	11
21	A three-year follow-up of hypnosis and restricted environmental stimulation therapy for smoking. <i>International Journal of Clinical and Experimental Hypnosis</i> , <b>1986</b> , 34, 169-81	1.8	27
20	Immunological response to stress in agoraphobia and panic attacks. <i>Biological Psychiatry</i> , <b>1986</b> , 21, 768-749	7.9	37
19	Dental anxiety--the development of a measurement model. <i>Acta Psychiatrica Scandinavica</i> , <b>1986</b> , 73, 559-65	6.5	15
18	Tricyclic antidepressants in the treatment of panic and anxiety disorders. <i>Psychosomatics</i> , <b>1986</b> , 27, 10-6	2.6	29
17	Monoamine Oxidase Inhibitors and Alprazolam in the Treatment of Panic Disorder and Agoraphobia. <i>Psychiatric Clinics of North America</i> , <b>1985</b> , 8, 49-62	3.1	19
16	Panic and Other Anxiety Disorders: Diagnosis and Treatment <b>1985</b> , 775-781		
15	Classification of Anxiety Disorders <b>1985</b> , 711-716		1
14	Some biochemical correlates of panic attacks with agoraphobia and their response to a new treatment. <i>Journal of Clinical Psychopharmacology</i> , <b>1984</b> , 4, 66-75	1.7	110
13	The diagnosis and drug treatment of anxiety disorders. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , <b>1983</b> , 7, 599-603	5.5	9



12	Panic attacks and phobias. <i>New England Journal of Medicine</i> , <b>1983</b> , 308, 341-3	59.2	2
11	Lack of Efficacy of a New Antidepressant (Bupropion) in the Treatment of Panic Disorder with Phobias. <i>Journal of Clinical Psychopharmacology</i> , <b>1983</b> , 3, 28-31	1.7	58
10	The classification of phobic disorders. <i>International Journal of Psychiatry in Medicine</i> , <b>1982</b> , 12, 243-66	1	66
9	Current concepts in psychiatry. Panic attacks and phobias. <i>New England Journal of Medicine</i> , <b>1982</b> , 307, 156-8	59.2	186
8	The Classification of Anxiety and Hysterical States. Part I. Historical Review and Empirical Delineation. <i>Journal of Clinical Psychopharmacology</i> , <b>1982</b> , 2, 235-244	1.7	18
7	The Classification of Anxiety and Hysterical States. Part II. Toward a More Heuristic Classification. <i>Journal of Clinical Psychopharmacology</i> , <b>1982</b> , 2, 386-393	1.7	34
6	Age of onset of phobic disorders: a reevaluation. <i>Comprehensive Psychiatry</i> , <b>1981</b> , 22, 544-53	7.3	90
5	Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. <i>Archives of General Psychiatry</i> , <b>1980</b> , 37, 51-9		583
4	Monoamine oxidase inhibitors: prescription and patient management. <i>International Journal of Psychiatry in Medicine</i> , <b>1980</b> , 10, 99-121	1	35
3	Empirical assessment of Spiegel's Hypnotic Induction Profile and eye-roll hypothesis. <i>International Journal of Clinical and Experimental Hypnosis</i> , <b>1979</b> , 27, 103-10	1.8	7
2	Influence of psychosocial factors on wart remission. <i>American Journal of Clinical Hypnosis</i> , <b>1978</b> , 20, 160-6	4.6	10
1	Psychiatric Aspects of Oral Contraceptive Use. <i>Psychiatric Annals</i> , <b>1976</b> , 6, 81-99	0.5	4